Millennium Management LLC Acquires 412,211 Shares of Qiagen NV (QGEN)

Millennium Management LLC boosted its holdings in shares of Qiagen NV (NYSE:QGEN) by 172.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 650,831 shares of the company’s stock after buying an additional 412,211 shares during the period. Millennium Management LLC owned approximately 0.29% of Qiagen worth $22,421,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of QGEN. Lindbrook Capital LLC purchased a new position in shares of Qiagen in the fourth quarter worth about $25,000. Captrust Financial Advisors grew its stake in shares of Qiagen by 165.3% in the fourth quarter. Captrust Financial Advisors now owns 1,008 shares of the company’s stock worth $35,000 after purchasing an additional 628 shares during the last quarter. Bremer Trust National Association bought a new stake in shares of Qiagen in the fourth quarter worth about $45,000. Fort L.P. bought a new stake in shares of Qiagen in the fourth quarter worth about $68,000. Finally, Oppenheimer Asset Management Inc. bought a new stake in shares of Qiagen in the fourth quarter worth about $118,000. 64.77% of the stock is owned by institutional investors.

QGEN has been the topic of several recent analyst reports. Zacks Investment Research raised Qiagen from a “sell” rating to a “buy” rating and set a $45.00 target price on the stock in a research note on Tuesday, April 16th. Deutsche Bank reissued a “buy” rating on shares of Qiagen in a research note on Friday, April 12th. Jefferies Financial Group reissued a “neutral” rating on shares of Qiagen in a research note on Monday, January 21st. Finally, UBS Group started coverage on Qiagen in a research report on Friday, March 15th. They set a “neutral” rating and a $42.00 price objective on the stock. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $41.71.

Shares of QGEN traded down $0.20 during mid-day trading on Wednesday, reaching $38.53. The company had a trading volume of 821,300 shares, compared to its average volume of 1,301,459. The company has a quick ratio of 2.05, a current ratio of 2.22 and a debt-to-equity ratio of 0.63. Qiagen NV has a 52 week low of $31.93 and a 52 week high of $41.55. The stock has a market cap of $8.64 billion, a P/E ratio of 28.75, a P/E/G ratio of 2.14 and a beta of 0.92.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Monday, February 4th. The company reported $0.40 EPS for the quarter, hitting analysts’ consensus estimates of $0.40. Qiagen had a return on equity of 12.15% and a net margin of 12.68%. The firm had revenue of $403.20 million for the quarter, compared to analysts’ expectations of $409.32 million. During the same period in the previous year, the firm posted $0.43 EPS. The business’s revenue for the quarter was up 1.6% compared to the same quarter last year. On average, equities analysts anticipate that Qiagen NV will post 1.46 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Millennium Management LLC Acquires 412,211 Shares of Qiagen NV (QGEN)” was first posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/04/24/qiagen-nv-qgen-shares-bought-by-millennium-management-llc.html.

Qiagen Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Recommended Story: Purposes and Functions of the Federal Reserve

Institutional Ownership by Quarter for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.